Domestic pharmaceutical firm plans NT$1.1 billion investment
Taipei, June 30 (CNA) ScinoPharm Taiwan Ltd., one of the leading biotechnology companies in the country, said Friday it plans to invest NT$1.1 billion (US$37.6 million) in a project to manufacture high-potency injectable drugs for cancer treatment.
Access to articles dating back more than six months is not available free of charge. You can gain access by becoming a paid Focus Taiwan member.
※This website's content, including but not limited to text, images and video, cannot be reproduced, retransmitted or publicly broadcast without the authorization of CNA.